-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski --
FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., , announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than 50 foreign countries and all 50 U.S. states.
One of the DFCon 09’s accepted abstracts this year is Activated Collagen: An Evidence Based Study (Interim Data) in Human Leg Ulcers. This abstract features Wound Care Innovations’ advanced wound care collagen gel CellerateRx(R) and was conducted by Dr. Matt Regulski, Director of Wound Care Center of Ocean County, NJ. Dr. Regulski graduated Summa Cum Laude from Temple University. He is Board-certified in wound care, an associate of the American College of Foot and Ankle Surgeons (ACFAS) and a partner of the Ocean County Foot and Ankle Surgery Association. He has published several wound care papers and is a frequent speaker at medical conferences.
Dr. Regulski commented, “The initial data shows that CellerateRx treated wounds were healed by six (6) weeks and the control wounds were approximately 60% healed at fourteen (14) weeks,” said Dr. Matt Regulski. “I was impressed by the speed and efficacy of CellerateRx. Diabetic ulcers remain one of the biggest problems and challenges that we face in healthcare today, both in terms of economic expenditures and patient welfare. Most amputations begin with an ulcer, so having a product that can help manage these wounds more effectively will save limbs and resources.” A copy of the abstract is available online at www.Celleraterx.com.
“Dr. Regulski is one of the nation’s leading specialists in diabetic wound care and limb salvage, and reconstructive surgery. We are honored to have him conducting evidence-based studies using our advanced wound care collagen product,” stated Cathy Bradshaw, president of Wound Care Innovations. “CellerateRx(R) is a one of a kind, patented collagen product that comes in a powder and a gel. It is FDA cleared for use for all acute and chronic wounds, except 3rd degree burns. The results from independent studies such as Dr. Regulski’s, in addition to positive feedback on CellerateRx from clinicians all over the world, indicate CellerateRx has strong potential to serve the global diabetic ulcer marketplace.”
About DFCon 09
DFCon is sponsored Providence Saint Joseph Medical Center and the Providence Diabetic Foot Center in cooperation with the International Conference Management, Inc. The program is designed for the wide spectrum of generalists and specialists who diagnose and manage the diabetic foot, delving into diagnostics and interventional strategies for diabetic foot ulcers and amputation prevention. Featuring a world-renowned faculty, DFCon 09 provides the opportunity to review state-of-the-art concepts and techniques. For more information on DFCon 09, visit www.DFCon.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. , with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company’s Website at www.Celleraterx.com.
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Cathy Bradshaw, President, Product Information, +1-954-315-9242,
or, Lucy Singleton, Secretary, Shareholder Relations, +1-817-820-7080
Web site: http://www.celleraterx.com//
